Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The cancer therapeutics market was valued at USD 240.78 Billion in 2025. It is poised to grow at a CAGR of 10.60% during the forecast period of 2026-2035, and reach USD 659.43 Billion by 2035. The market growth is driven by the rising global cancer burden, expanding immuno-oncology and targeted therapy pipelines, increasing FDA approvals across solid tumors and hematologic malignancies, and growing adoption of precision medicine in routine clinical practice.
Latest News on the Cancer Therapeutics Market (2026)
April 2026: AACR 2026 Showcases Next-Wave VEGF and Bispecific Oncology Pipelines
The American Association for Cancer Research Annual Meeting 2026 drew more than 22,000 participants, with Merck unveiling competitive VEGF inhibitor data alongside parallel readouts from Akeso, Summit Therapeutics, BioNTech, Bristol Myers Squibb, Pfizer and Shanghai-based 3SBio. Reuters reported that the conference reinforced the centrality of antibody-drug conjugates and bispecific antibodies in shaping near-term oncology revenue growth, with Chinese biotech licensing deals continuing to underpin pipeline expansion across major Western pharmaceutical companies.
March 2026: FDA Approves Nivolumab Combination for Advanced Hodgkin Lymphoma
The FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine and dacarbazine chemotherapy for adult and paediatric patients twelve years and older with previously untreated stage 3 or 4 classical Hodgkin lymphoma. As reported by The New York Times, the approval marks a significant shift toward earlier integration of immune checkpoint inhibitors in haematologic malignancy treatment, complementing the first-quarter approval of relacorilant (Lifyorli) for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer.
Key Market Trends and Insights
- Based on cancer type, the lung cancer segment is likely to dominate the market in the forecast period.
- Based on the distribution channel, the hospital pharmacies segment accounted for around 48% of the market share in the historical period.
- Based on the region, North America held over 45% market share in the historical period.
Market Size and Forecast
- Market Size (2025): USD 240.78 Billion
- Projected Market Size (2035): USD 659.43 Billion
- CAGR (2026-2035): 10.60%
- Largest Market in 2025: North America
Compound Annual Growth Rate
10.6%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer Therapeutics Market Overview
Cancer therapeutics continue to evolve through advancements in targeted therapies, immunotherapies, hormone therapies, and precision medicine approaches that improve treatment outcomes and patient survival rates. The market reached a value of approximately USD 240.78 Billion in 2025, and is anticipated to witness robust expansion, supported by rising global cancer incidence, accelerating regulatory approvals for novel oncology drugs, and broadening adoption of precision medicine across solid tumors and hematologic malignancies. The shift toward biomarker-defined patient selection and combination immunotherapy regimens is driving incremental clinical benefit, while antibody-drug conjugates, bispecific antibodies, and cellular therapies are expanding the oncology drugs across multiple lines of care.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer Therapeutics Market Segmentation
Market Breakup by Treatment Type
- Therapy Type
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
- Radiation Therapy
- Stem Cell Therapy
- Gene Therapy
- Others
- Drug Class
- Alkylating Agents
- Antimetabolites
- Antitumor Antibiotics
- Topoisomerase Inhibitors
- Mitotic Inhibitors
- Hormone Therapies
- Immune Checkpoint Inhibitors
- Others
The market is segmented by treatment type into therapy type and drug class, reflecting the expanding diversity of oncology treatment approaches across different cancer indications. The growing adoption of immunotherapy, targeted therapy, hormone-based treatments, and next-generation oncology drugs is supporting market growth, while continuous advancements in precision medicine and combination treatment regimens are further improving therapeutic outcomes and expanding clinical applications across cancer care settings.
Market Breakup by Cancer Type
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Head and Neck Cancer
- Brain Tumors
- Others
The market is segmented by cancer type into blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, head and neck cancer, brain tumors, and others, reflecting the broad therapeutic application of oncology treatments across hematologic and solid malignancies. Lung and breast cancer segments are expected to account for substantial demand due to rising incidence rates, growing adoption of targeted biologics, and increasing availability of precision medicine approaches in advanced cancer care.
Market Breakup by Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Others
By route of administration, the market includes oral, intravenous, subcutaneous, and other routes. Intravenous administration dominates due to the widespread use of infused chemotherapy and biologics in hospital and infusion-center settings, while oral oncology drugs are expanding rapidly with the rise of tyrosine kinase inhibitors and oral cytotoxics. Subcutaneous formulations are gaining clinical preference for select biologics through reduced infusion therapy burden and improved patient convenience.
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Cancer Centers
- Others
Based on end user, the market is divided into hospitals, specialty clinics, cancer centers, and others, with hospitals maintaining a leading share due to the availability of advanced oncology infrastructure, multidisciplinary treatment capabilities, and high patient admission rates. Cancer centers are increasingly gaining traction with the growing preference for specialized oncology drugs, expanded access to clinical trials, and rising investments in comprehensive cancer treatment facilities.
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies dominate the market due to high volumes of infused chemotherapy and immunotherapy administered in inpatient and outpatient settings, while other pharmacies are growing rapidly to support oral targeted therapies and complex biologics requiring patient counseling and adherence support.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate due to advanced oncology research infrastructure, the highest concentration of FDA approvals, and strong reimbursement frameworks for novel cancer drugs. Asia Pacific is anticipated to expand rapidly, supported by rising healthcare expenditure and growing access to innovative cancer diagnostics options across China, Japan, and India.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer Therapeutics Market Growth Analysis and Key Influencers
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Rising global cancer burden and expanding immuno-oncology pipelines |
According to the WHO, cancer causes nearly 10 million deaths annually, increasing the need for innovative therapeutics globally. |
|
Market Restraints |
High treatment cost and limited access in low- and middle-income countries |
CAR T-cell therapies often cost several hundred thousand USD per patient, limiting widespread adoption and affordability. |
|
Market Opportunities |
Growth of biomarker-driven precision oncology and combination regimens |
In March 2026, the FDA approved Lifyorli with nab-paclitaxel for platinum-resistant ovarian cancer treatment. |
Cancer Therapeutics Market Dynamics
This section analyzes key factors influencing market growth, including disease burden, regulatory drivers, technology adoption, cost dynamics, and ecosystem shifts.
Cancer Therapeutics Market Drivers
Rising Global Cancer Burden to Drive the Market Expansion
The market is witnessing strong growth driven by the rising global incidence of cancer and the rapidly expanding pipeline of novel cancer drugs across the cancer immunotherapy landscape. According to the World Health Organization, cancer is responsible for an estimated 10 million deaths annually worldwide, and incidence is projected to continue rising with population aging. The growing global cancer burden and continuous expansion of innovative oncology pipelines are expected to accelerate demand for advanced cancer immunotherapies, thereby supporting sustained market growth during the forecast period.
Cancer Therapeutics Market Restraints
High Treatment Cost and Access Barriers Limiting Market Penetration
The high cost of novel cancer therapies, particularly cell therapies and antibody-drug conjugates, remains a significant restraint, especially in low- and middle-income countries where reimbursement for high-priced biologics is limited and out-of-pocket affordability is constrained. List prices for CAR T-cell therapies frequently exceed several hundred thousand US dollars per patient, restricting widespread global access to the latest targeted therapy options. However, the growing pipeline of biosimilars for oncology biologics, alongside expanding patient assistance programs and value-based contracting in major markets, is gradually broadening affordability and supporting sustained adoption across the cancer therapeutics market during the forecast period.
Cancer Therapeutics Market Opportunities
Precision Oncology and Antibody-Drug Conjugates Creating Strong Opportunities
The expansion of biomarker-driven precision oncology and the rapid development of antibody-drug conjugates and bispecific antibodies are creating significant growth opportunities, supported by improved tumor response rates and tolerability profiles. For instance, in March 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, marking the first oncology approval based on selective glucocorticoid receptor antagonism. These advances are expanding the addressable patient population and reinforcing the role of precision-based combination strategies across the antibody drug conjugates segment of the market.
Cancer Therapeutics Market Trends
Cellular Therapies and Combination Immunotherapy Shaping Market Landscape
The growing emphasis on cellular therapies and combination immunotherapy is a key trend shaping the market, supported by long-term durability evidence from CAR T-cell pivotal trials and earlier-line integration of checkpoint inhibitors. For instance, in April 2026, the FDA converted brexucabtagene autoleucel (Tecartus) from accelerated to full approval for relapsed or refractory mantle cell lymphoma based on the totality of evidence from the phase 2 ZUMA-2 trial. These developments are accelerating clinical adoption of advanced cell therapies and reinforcing growth across the hematology segment of the cancer therapeutics market during the forecast period.
Cancer Therapeutics Market Share
Hospital Pharmacies Likely to Dominate the Market Segment by Distribution Channel
The hospital pharmacies segment is likely to lead, supported by centralized drug procurement, strong oncology infusion infrastructure, and access to high-cost biologics and chemotherapy regimens. Hospitals remain primary treatment settings for complex cancer cases, ensuring consistent demand. Additionally, integration with oncology drug delivery systems enhances treatment efficiency, safety monitoring, and dosing precision, further reinforcing the segment’s sustained relevance across global healthcare systems.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Cancer Therapeutics Market Analysis by Region
The North America segment is likely to witness significant growth in the market, supported by advanced healthcare infrastructure, high cancer prevalence, and strong reimbursement frameworks for innovative therapies. The region benefits from the rapid adoption of targeted treatments and immunotherapies across leading cancer centers. Moreover, increasing utilization of precision oncology solutions is improving patient outcomes, supporting early diagnosis, and driving continued demand across the regional cancer therapeutics market landscape.
Leading Players in the Cancer Therapeutics Market
AstraZeneca
AstraZeneca, headquartered in Cambridge, United Kingdom, was formed in 1999 through the merger of Astra AB and Zeneca Group plc and operates across oncology, cardiovascular, respiratory, and rare disease therapy areas. Its oncology portfolio spans Tagrisso, Imfinzi, Lynparza, and Enhertu (in collaboration with Daiichi Sankyo), strengthening its leadership across NSCLC, breast, ovarian, and bladder cancers.
Bristol-Myers Squibb
Bristol-Myers Squibb, headquartered in New York, United States, was founded in 1887 and is a global biopharmaceutical company specializing in immunology, oncology, cardiovascular, and hematology. Its oncology portfolio includes Opdivo, Yervoy, Reblozyl, and Breyanzi, contributing significantly to the immune checkpoint inhibitor and cell therapy segments of the cancer therapeutics market.
Eli Lilly and Company
Eli Lilly and Company, headquartered in Indianapolis, Indiana, United States, was founded in 1876 and operates across diabetes, oncology, immunology, and neuroscience. Its oncology portfolio includes Verzenio, Retevmo, and Cyramza, supporting strong positions in HR-positive breast cancer, RET-altered cancers, and gastric and NSCLC indications.
F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG, headquartered in Basel, Switzerland, was founded in 1896 and is a global leader in pharmaceuticals and diagnostics. Its oncology portfolio includes Avastin, Herceptin, Perjeta, Kadcyla, Tecentriq, and Polivy through its Genentech and Chugai subsidiaries, reinforcing its strong position across breast cancer, NSCLC, hematology, and the broader oncology landscape.
Other key players include AbbVie Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., Pfizer Inc., Novartis AG, and Merck KGaA.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Cancer Therapeutics Market Report
- What was the cancer therapeutics market value in 2025?
- What is the cancer therapeutics market forecast outlook for 2026-2035?
- What major factors aid the demand for the cancer therapeutics market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major cancer therapeutics market trends?
- Which treatment type is expected to dominate the market segment?
- Which cancer type is expected to dominate the market segment?
- Which route of administration is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Which distribution channel is expected to dominate the market segment?
- Who are the key players in the cancer therapeutics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$5499 $4949
-
$3299 $2969
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Cancer Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
